BrainsWay Changes ADS Ratio to 1:1 Structure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy BWAY?
Source: seekingalpha
- ADS Ratio Change: BrainsWay Ltd. announced a change in its American Depositary Shares (ADS) to a 1-to-1 ratio from the current 2-to-1, effective before trading begins on March 3, resulting in each existing ADS holder receiving an additional ADS, effectively a 2-for-1 forward split.
- Market Impact: The company indicated that the trading price of its ADSs is expected to be halved following the ratio change, which may influence short-term holding decisions among investors, although ordinary shares remain unaffected by this adjustment.
- No Action Required: BrainsWay noted that ADS holders are not required to take any action to accommodate this change, a convenience aimed at reducing operational complexity for investors and maintaining market stability.
- Stock Performance: Following the announcement, BrainsWay's stock price surged by 32.18%, closing at $11.54, reflecting a positive market reaction to the adjustment, although future price volatility remains a concern.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BWAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BWAY
Wall Street analysts forecast BWAY stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.660
Low
19.00
Averages
26.33
High
30.00
Current: 12.660
Low
19.00
Averages
26.33
High
30.00
About BWAY
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BrainsWay to Announce Q4 Earnings on March 11
- Earnings Announcement: BrainsWay is set to release its Q4 earnings on March 11 before market open, with consensus EPS estimated at $0.03, reflecting a 25% year-over-year decline, while revenue is projected at $14.02 million, indicating a 22.9% year-over-year increase.
- Consistent Outperformance: Over the past year, BrainsWay has consistently beaten both EPS and revenue estimates, achieving a 100% success rate, which underscores its strong financial performance and market confidence.
- Investment Impact: Despite a recent decline in stock price following an investment in a Canadian mental care provider, BrainsWay remains a focal point in the industry, particularly given the ongoing demand for mental health services.
- Market Insights: According to Seeking Alpha's Quant Rating, BrainsWay's financial health is robust, and despite competitive pressures, its strategic positioning in the mental health market remains significant.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: In the healthcare sector, Gossamer Bio Inc, Brainsway Ltd, and Definitive Healthcare Corp have relative strength indices (RSI) near or below 30, indicating these stocks are significantly undervalued and may present buying opportunities for investors.
- RSI Indicator Interpretation: The relative strength index (RSI) serves as a momentum indicator that compares a stock's strength on up days versus down days, helping traders better assess short-term stock performance, particularly in oversold conditions.
- Market Opportunity Analysis: According to Benzinga Pro, assets are typically considered oversold when the RSI is below 30, providing investors with opportunities to identify potential rebound stocks within the healthcare sector that could yield substantial returns.
- Investment Strategy Recommendations: Investors should focus on the fundamentals and market dynamics of these oversold stocks to make informed investment decisions at the right time, thereby capitalizing on profit opportunities arising from market fluctuations.
See More
BrainsWay Unveils New Noninvasive Depression Treatment Protocol
- Clinical Data Breakthrough: BrainsWay's new clinical data reveals that its FDA-cleared SWIFT™ accelerated Deep TMS protocol achieves an 87.8% response rate and a 78.0% remission rate for Major Depressive Disorder, significantly reducing treatment time from 20 sessions to just 6 half days, enhancing patient experience and adherence.
- Improved Quality of Life: The study indicates that approximately 70% of participants no longer suffer from severe quality of life impairment, and about 60% returned to normal functioning post-treatment, demonstrating that SWIFT™ not only succeeds statistically but also helps patients regain work and relationships in real life.
- Reduced Treatment Burden: By cutting clinic visits in the acute phase by around 70%, SWIFT™ effectively addresses logistical barriers such as time and travel, which is expected to transform how interventional psychiatry is delivered, improving patient accessibility and satisfaction.
- Industry Transformation Outlook: BrainsWay's CEO states that the launch of SWIFT™ marks the beginning of a new era in mental health, emphasizing that innovation must focus on both clinical efficacy and addressing accessibility and scalability, driving advancements in neuroscience.
See More
BrainsWay to Report Q4 and Full Year 2025 Results on March 11
- Earnings Announcement: BrainsWay will report its Q4 and full year 2025 financial results before the U.S. market opens on March 11, 2026, highlighting the company's ongoing advancements in noninvasive neurostimulation technologies.
- Conference Call Details: The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the financial results and provide updates on business operations, ensuring investors receive timely and critical information.
- Technological Leadership: BrainsWay is the first and only TMS company to obtain three FDA-cleared indications, focusing on treating major depressive disorder, obsessive-compulsive disorder, and smoking addiction, showcasing its innovative capabilities and clinical efficacy in mental health.
- Clinical Trial Progress: The company is conducting multiple clinical trials of Deep TMS aimed at expanding its applications in psychiatric, neurological, and addiction disorders, further solidifying its market leadership position.
See More
BrainsWay to Announce Q4 Earnings on March 11
- Earnings Announcement: BrainsWay is set to release its Q4 earnings on March 11 before market open, with consensus EPS estimated at $0.03, reflecting a 25% year-over-year decline, while revenue is projected at $14.02 million, indicating a 22.9% year-over-year increase.
- Consistent Outperformance: Over the past year, BrainsWay has consistently beaten both EPS and revenue estimates, achieving a 100% success rate, which underscores its strong financial performance and market confidence.
- Investment Impact: Despite a recent decline in stock price following an investment in a Canadian mental care provider, BrainsWay remains a focal point in the industry, particularly given the ongoing demand for mental health services.
- Market Insights: According to Seeking Alpha's Quant Rating, BrainsWay's financial health is robust, and despite competitive pressures, its strategic positioning in the mental health market remains significant.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: In the healthcare sector, Gossamer Bio Inc, Brainsway Ltd, and Definitive Healthcare Corp have relative strength indices (RSI) near or below 30, indicating these stocks are significantly undervalued and may present buying opportunities for investors.
- RSI Indicator Interpretation: The relative strength index (RSI) serves as a momentum indicator that compares a stock's strength on up days versus down days, helping traders better assess short-term stock performance, particularly in oversold conditions.
- Market Opportunity Analysis: According to Benzinga Pro, assets are typically considered oversold when the RSI is below 30, providing investors with opportunities to identify potential rebound stocks within the healthcare sector that could yield substantial returns.
- Investment Strategy Recommendations: Investors should focus on the fundamentals and market dynamics of these oversold stocks to make informed investment decisions at the right time, thereby capitalizing on profit opportunities arising from market fluctuations.
See More
BrainsWay Unveils New Noninvasive Depression Treatment Protocol
- Clinical Data Breakthrough: BrainsWay's new clinical data reveals that its FDA-cleared SWIFT™ accelerated Deep TMS protocol achieves an 87.8% response rate and a 78.0% remission rate for Major Depressive Disorder, significantly reducing treatment time from 20 sessions to just 6 half days, enhancing patient experience and adherence.
- Improved Quality of Life: The study indicates that approximately 70% of participants no longer suffer from severe quality of life impairment, and about 60% returned to normal functioning post-treatment, demonstrating that SWIFT™ not only succeeds statistically but also helps patients regain work and relationships in real life.
- Reduced Treatment Burden: By cutting clinic visits in the acute phase by around 70%, SWIFT™ effectively addresses logistical barriers such as time and travel, which is expected to transform how interventional psychiatry is delivered, improving patient accessibility and satisfaction.
- Industry Transformation Outlook: BrainsWay's CEO states that the launch of SWIFT™ marks the beginning of a new era in mental health, emphasizing that innovation must focus on both clinical efficacy and addressing accessibility and scalability, driving advancements in neuroscience.
See More
BrainsWay to Report Q4 and Full Year 2025 Results on March 11
- Earnings Announcement: BrainsWay will report its Q4 and full year 2025 financial results before the U.S. market opens on March 11, 2026, highlighting the company's ongoing advancements in noninvasive neurostimulation technologies.
- Conference Call Details: The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the financial results and provide updates on business operations, ensuring investors receive timely and critical information.
- Technological Leadership: BrainsWay is the first and only TMS company to obtain three FDA-cleared indications, focusing on treating major depressive disorder, obsessive-compulsive disorder, and smoking addiction, showcasing its innovative capabilities and clinical efficacy in mental health.
- Clinical Trial Progress: The company is conducting multiple clinical trials of Deep TMS aimed at expanding its applications in psychiatric, neurological, and addiction disorders, further solidifying its market leadership position.
See More
